Form4insider filings, from the source

SEC Form 4 · accession 0001635088-26-000071

Roivant Sciences Ltd. · ROIV

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Eric Venker
Officer — President & Immunovant CEO
Period of report
Jun 24, 2026
Accepted (ET)
Jun 26, 2026 · 6:13 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001635088

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common SharesJun 24, 2026M200,000$3.85A1,813,063D
Common SharesF1Jun 24, 2026S153,766$33.05D1,659,297D
Common SharesF2Jun 24, 2026S46,234$33.51D1,613,063D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F3$3.85Jun 24, 2026M200,000D—Apr 19, 2032Common Stock200,0004,244,834D

Explanation of responses